Page 102 - Amgen News Today

HB Wealth Management LLC reduced its stake in shares of Amgen Inc. (NASDAQ:AMGN – Free Report) by 3.5% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 36,428 shares of the medical research company’s stock after selling 1,327 shares during the period. HB […]

Twelve Points Wealth Management LLC grew its holdings in shares of Amgen Inc. (NASDAQ:AMGN – Free Report) by 5.6% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,628 shares of the medical research company’s stock after purchasing an additional 87 shares […]

The Amgen Scholars Program (ASP) is an international program funded by the Amgen Foundation with the direction of Harvard University, aiming to increase ...

Ozempic maker Novo Nordisk and Mounjaro maker Eli Lilly dominate the lucrative weight loss drug market with Wegovy and Zepbound, but companies are racing to compete in one of the most lucrative markets in the history of the pharmaceutical industry.

B. Riley Wealth Advisors Inc. decreased its stake in shares of Amgen Inc. (NASDAQ:AMGN – Free Report) by 56.7% during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 43,207 shares of the medical research company’s stock after selling 56,581 shares during the period. B. Riley Wealth […]

CAMBRIDGE, Mass., March 12, 2024 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develo...

Tucker Asset Management LLC grew its position in shares of Amgen Inc. (NASDAQ:AMGN – Free Report) by 15.1% during the 3rd quarter, Holdings Channel.com reports. The institutional investor owned 669 shares of the medical research company’s stock after buying an additional 88 shares during the quarter. Tucker Asset Management LLC’s holdings in Amgen were worth […]

Bristol Myers Squibb has pulled the plug on a more potent version of its cancer immunotherapy Yervoy. However, the two companies will continue to work on other collaborative programs for T-cell engagers.

Executive Advisor at professional service organization Kymanox.

CytomX Therapeutics, Inc. (NASDAQ:CTMX) Q4 2023 Earnings Call Transcript March 11, 2024 CytomX Therapeutics, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good day, and thank you for standing by. Welcome to the CytomX Therapeutics Fourth Quarter 2023 Financial […]